ALS Cure Roadmap

ALS Cure Roadmap

Overview

Amyotrophic Lateral Sclerosis (ALS) Cure Roadmap provides a comprehensive framework for understanding the current state of therapeutic development for ALS, a fatal neurodegenerative disorder characterized by progressive loss of upper and lower motor neurons. This roadmap synthesizes insights from genetic discoveries, molecular pathology, and clinical trials to identify promising routes to disease modification and ultimately a cure.

ALS is part of a broader neurodegenerative spectrum with Frontotemporal Dementia (FTD), with approximately 15% of ALS patients meeting criteria for FTD and up to 50% showing some degree of cognitive or behavioral impairment. This clinical overlap reflects shared molecular mechanisms, particularly TDP-43 pathology and C9orf72 hexanucleotide repeat expansions. [@chen2023]

Related: [ALS Pathway](/mechanisms/als-pathway) | [ALS Knowledge Gaps](/mechanisms/als-knowledge-gaps-ranked) | [FTD Cure Roadmap](/mechanisms/ftd-cure-roadmap) | [Experiment Priority Index](/experiments/experiment-priority-index)

Current Therapeutic Landscape

Approved Treatments

ALS Cure Roadmap

Overview

Amyotrophic Lateral Sclerosis (ALS) Cure Roadmap provides a comprehensive framework for understanding the current state of therapeutic development for ALS, a fatal neurodegenerative disorder characterized by progressive loss of upper and lower motor neurons. This roadmap synthesizes insights from genetic discoveries, molecular pathology, and clinical trials to identify promising routes to disease modification and ultimately a cure.

ALS is part of a broader neurodegenerative spectrum with Frontotemporal Dementia (FTD), with approximately 15% of ALS patients meeting criteria for FTD and up to 50% showing some degree of cognitive or behavioral impairment. This clinical overlap reflects shared molecular mechanisms, particularly TDP-43 pathology and C9orf72 hexanucleotide repeat expansions. [@chen2023]

Related: [ALS Pathway](/mechanisms/als-pathway) | [ALS Knowledge Gaps](/mechanisms/als-knowledge-gaps-ranked) | [FTD Cure Roadmap](/mechanisms/ftd-cure-roadmap) | [Experiment Priority Index](/experiments/experiment-priority-index)

Current Therapeutic Landscape

Approved Treatments

| Treatment | Mechanism | Indication | Efficacy |
|-----------|-----------|------------|----------|
| Riluzole | Glutamate modulation, anti-excitotoxicity | ALS | Modest survival benefit (2-3 months) [@van2017] |
| Edaravone | Antioxidant, anti-oxidative stress | ALS (Japan/US) | Slows functional decline in early-stage patients |
| Tofersen (AMIAS) | SOD1 ASO | SOD1-associated ALS | Significant SOD1 reduction, clinical benefit in fast-progressors |
| Relyvrio (Sodium phenylbutyrate/taurursodiol) | Antioxidant, autophagy induction | ALS | Modest functional benefit |

Clinical Trials Landscape

• 200+ clinical trials in ALS currently active or recently completed
• High failure rate: 95%+ of ALS clinical trials have failed to meet primary endpoints
• Key challenges: Clinical heterogeneity, inadequate biomarkers, trial design issues

Genetic Subtypes and Targeted Approaches

Approximately 10-15% of ALS cases are familial, with the major genetic causes being:

| Gene | Protein | Pathology | % of Familial ALS | Therapeutic Approach |
|------|---------|-----------|-------------------|---------------------|
| C9orf72 | C9orf72 protein | TDP-43 + DPR | ~40% | ASOs targeting repeat expansion, gene therapy |
| SOD1 | Superoxide dismutase 1 | SOD1 aggregates | ~20% | ASOs (tofersen approved), gene therapy |
| FUS | Fused in sarcoma | FUS aggregates | ~5% | RNA targeting, autophagy modulators |
| TARDBP | TDP-43 | TDP-43 aggregates | ~5% | Splicing modulators, autophagy enhancers |
| VCP | Valosin-containing protein | TDP-43 | ~5% | Autophagy modulators |
| TBK1 | TANK-binding kinase 1 | TDP-43 | ~3% | Autophagy and neuroinflammation targeting |

The identification of these genetic drivers has enabled precision medicine approaches that are now entering clinical trials.

Therapeutic Target Map

1. Gene-Specific Approaches

2. Shared Mechanisms Across All ALS Subtypes

| Mechanism | Therapeutic Target | Status |
|-----------|-------------------|--------|
| TDP-43 pathology | Aggregation inhibitors, autophagy enhancers | Preclinical/Phase 1 |
| Neuroinflammation | TREM2 agonists, CSF1R inhibitors, anti-inflammatory | Phase 1/2 |
| Oxidative stress | Antioxidants (edaravone approved), NRF2 activators | Approved/Phase 2 |
| Excitotoxicity | AMPA/kainate receptor antagonists, glutamate modulation | Approved (riluzole) |
| Mitochondrial dysfunction | Mitochondrial protectants, mitophagy enhancers | Preclinical/Phase 1 |
| Axonal transport defects | Microtubule stabilizers, transport enhancers | Preclinical |
| Metabolic dysfunction | Metabolic modulators, energetic enhancers | Phase 2 |

Phase 1: Diagnosis Confirmation and Symptomatic Management (NOW)

Goal: Accurate genetic diagnosis, symptom optimization, biomarker baseline

| Action | Status | Timeline |
|--------|--------|----------|
| Confirmatory genetic testing (C9orf72, SOD1, FUS panel) | Available | Week 1 |
| Baseline neurological exam (ALSFRS-R, force vital capacity) | Standard of care | Week 1 |
| Blood biomarker panel (NfL, pNfH, GFAP) | Available | Week 1 |
| Electromyography (EMG) for diagnosis confirmation | Standard of care | Week 1-2 |
| Genetic counseling for family members | Standard of care | Week 2 |
| Riluzole initiation | FDA approved | Week 1 |
| Edaravone initiation (if eligible) | FDA approved | Week 2 |
| Multidisciplinary care (neurology, pulmonology, PT, OT, speech) | Standard of care | Ongoing |
| Non-invasive ventilation (if FVC < 80%) | Standard of care | As needed |

Understanding gaps at this phase:

• What determines progression rate in individual patients?
• Can NfL trajectory predict rate of decline?
• When is optimal time to initiate disease-modifying therapy?

Phase 2: Disease Modification Trials (2025-2028)

Goal: Slow or halt disease progression through targeted therapies

C9orf72-Targeted Approaches

C9orf72 hexanucleotide repeat expansion is the most common genetic cause of ALS/FTD. Two pathological mechanisms require targeting:

| Agent | Company | Mechanism | Trial Status | Expected Data |
|-------|---------|-----------|--------------|---------------|
| WVE-004 | Wave Life Sciences | C9orf72 ASO (repeat-containing) | Phase 1/2 (on hold) | Paused - strategic decision |
| BIIB078 | Biogen | C9orf72 ASO | Phase 1 (discontinued) | No clinical benefit |
| ASO-mediated | Various | Allele-selective | Preclinical | 2027+ |

Key learnings: C9orf72 ASO programs have faced challenges - the goal is to reduce toxic RNA species while preserving protein expression. Current approaches may require optimization for brain penetration and delivery.

SOD1-Targeted Approaches

| Agent | Company | Mechanism | Trial Status | Expected Data |
|-------|---------|-----------|--------------|---------------|
| Tofersen (BIIB067) | Biogen/Ionis | SOD1 ASO | Approved (2023) | Ongoing extension study |
| Ionis-SOD1Rx | Ionis | SOD1 ASO | Phase 1 (completed) | Safety established |
| AAV-SOD1 | Various | Gene therapy | IND-enabling | 2026-2027 |

Key learnings from tofersen: Significant SOD1 reduction in CSF, clinical benefit in patients with faster progression. Early intervention may be critical.

TDP-43 Aggregation Inhibitors

TDP-43 pathology is present in 97% of ALS cases. Novel approaches include:

• Small molecules targeting TDP-43 aggregation
• Autophagy enhancers (e.g., rapamycin analogs, TFEB activators)
• Splicing modulators to restore normal TDP-43 processing

Neuroinflammation Modulators

| Target | Approach | Status |
|--------|----------|--------|
| TREM2 | Agonists to enhance microglial clearance | Phase 1 (AD) |
| CSF1R | Inhibitors to modulate microglia | Phase 2 |
| IL-6 | Anti-IL-6 receptor antibodies | Phase 2 |

Phase 3: Combination Therapy and Precision Medicine (2027-2030)

Goal: Multi-target intervention tailored to individual patient biology

Rationale for Combination

Given ALS's complex pathophysiology, combining multiple mechanisms may provide synergistic benefit:

| Combination | Rationale | Status |
|-------------|-----------|--------|
| ASO + Neuroinflammation modulator | Target genetic cause + downstream inflammation | Preclinical |
| Anti-excitotoxicity + Antioxidant | Riluzole + Edaravone synergy | Phase 2 |
| Autophagy enhancer + TDP-43 inhibitor | Enhance aggregate clearance | Preclinical |
| Gene therapy + Small molecule | Genetic targeting + pathway modulation | Preclinical |

Precision Medicine Approaches

Phase 4: Prevention and Cure (2030+)

Goal: Prevent disease onset in at-risk individuals

Strategies

Biomarker Development

Fluid Biomarkers

| Biomarker | Target | Status | Utility |
|-----------|--------|--------|---------|
| NfL | Neurofilament light chain | Validated | Disease progression, prognosis |
| pNfH | Phosphorylated neurofilament heavy | Validated | Disease progression |
| GFAP | Glial fibrillary acidic protein | Clinical | Astrocyte activation |
| TDP-43 | TDP-43 in CSF | Research | Pathology burden |
| SOD1 | SOD1 in CSF | Validated | Target engagement (SOD1) |

Imaging Biomarkers

| Modality | Target | Status | Utility |
|----------|--------|--------|---------|
| MRI | Cortical thinning, white matter integrity | Standard | Disease progression |
| PET (FDG) | Metabolic patterns | Clinical | FTD overlap |
| PET (Pittsburgh B) | Neuroinflammation | Research | Microglial activation |

Clinical Endpoint Biomarkers

• ALSFRS-R: Functional rating scale (primary endpoint)
• FVC: Pulmonary function (survival predictor)
• QMA: Quantitative motor assessment
• Timed Up and Go: Mobility assessment

Clinical Trial Design Challenges

Current Challenges

Proposed Solutions

Research Priorities

Short-Term (2025-2027)

Medium-Term (2027-2030)

Long-Term (2030+)

Key Knowledge Gaps

From ALS Knowledge Gaps Analysis

| Gap | Priority | Therapeutic Impact |
|-----|----------|-------------------|
| C9orf72 DPR toxicity mechanism | High | Target identification |
| TDP-43 propagation mechanism | High | Biomarker, therapy |
| Selective motor neuron vulnerability | High | Prevention target |
| Microglia-neuron interaction | Medium | Immunotherapy |
| Non-motor neuron contributions | Medium | Broader therapy |
| Environmental risk factors | Medium | Prevention |

Projected Therapeutic Timeline

Near-Term (2025-2028)

Mid-Term (2028-2032)

Long-Term (2032+)

References